PASWFL is Now Offering Accelerated iTBS Treatment

What is Accelerated iTBS?

Accelerated iTBS shortens the treatment time for Theta Burst Stimulation even further. Where TBS consists of daily, 6 min 24 sec minute treatments for 2 weeks, Accelerated iTBS offers the same results in just 5 days of consecutive treatment with 10 iTBS treatments administered per day. Each daily sequence lasts around 9 minutes (1800 stimulus, 50 minutes pause then repeats 9 minutes until 10 treatments have been completed. Since the treatments have no significant side-effects it does not have to interfere with the rest of your day.

The Study Below Describes Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression

Depression is the leading cause of disability worldwide, and approximately 800,000 suicides occur each year (1–3). New antidepressant treatments are needed that are safe, tolerable, rapid acting, durable, and effective. Repetitive transcranial magnetic stimulation (rTMS) delivered to the left dorsolateral prefrontal cortex (DLPFC) is a noninvasive brain stimulation technique approved by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression.

A more efficient form of rTMS, known as intermittent theta-burst stimulation (iTBS), recently approved by the FDA, has significantly shortened the duration of rTMS treatment sessions from 37 minutes to 6 minutes and produces equivalent antidepressant responses. FDA approved rTMS and iTBS courses involve daily stimulation sessions (1200 iTBS pulses) for 2 weeks, and one trial has demonstrated remission in 32% of patients reach remission and response in 49%.Studies suggest that the efficacy of iTBS might be improved by accelerated, spaced delivery of stimulation sessions (50), higher overall pulse doses, and individualized targeting. We investigated the safety, tolerability, and preliminary efficacy of an accelerated high-dose iTBS protocol. This protocol involved 5 consecutive days (Monday through Friday) of 10 iTBS sessions per day.

Our initial investigation demonstrated efficacy in a small cohort of participants with severe and treatment-refractory depression (these participants are not included in the present study). The aim of this study was to examine the safety, feasibility, and preliminary efficacy of an accelerated, high-dose, fcMRI guided iTBS treatment protocol (SAINT) for treatment resistant depression. We found that SAINT significantly reduced depressive symptoms and suicidal ideation in patients with treatment-resistant depression within 5 days, without negative cognitive side effects.

The remission rate we observed is higher than reported open-label remission rates for standard FDA-approved rTMS protocols (37%) (13, 35, 36), ECT (;48%), and ketamine (31%) for treating treatment-resistant depression.

This is an abstract from the full study which can be read HERE.

Are you interested in iTBS for Treatment Resistant Depression? Contact Us for More Information.